Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Staging of Heart Failure with Preserved Ejection Fraction
Author(s): Anastasia Shchendrygina , Ilya Giverts , Mariya Tokmakova , et al Added: 7 months ago

Imaging & Diagnostics

Heart Failure
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
HFSA 24: FINEARTS-HF Across the Ejection Fraction Spectrum
Author(s): Akshay S Desai Added: 8 months ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3… View more

Heart Failure
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 6 months ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 6 months ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure
Liver Stiffness to Assess Central Venous Pressure in HF
Author(s): Nicolas Girerd Added: 3 weeks ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive… View more

Cardiovascular Renal Metabolic

Heart Failure
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 2 years ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
Timing of SGLT2 Inhibitors in Heart Failure
Author(s): Moritake Iguchi , Hiromichi Wada , Felipe Martínez , et al Added: 2 years ago

Heart Failure

Prevention & Chronic Conditions
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 3 weeks ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
AHA 24 Late-Breaking Discussion: The SUMMIT Trial
Author(s): Harriette Van Spall , Milton Packer Added: 6 months ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating… View more

Heart Failure

Prevention & Chronic Conditions